Conexeu says CXU preclinical program completes 12-month P.R.O.O.F. phase, meets objectives

Conexeu disclosed completion of the 12-month P.R.O.O.F. phase in its CXU preclinical program for an ECM-based biomaterial scaffold.

• The study met predefined objectives in a small-volume facial tissue model, and also in a large-volume subcutaneous model at about 200cc-equivalent volume.
• The company said the program is investigational and in the preclinical stage, positioning CXU as a multi-component collagen-ECM scaffold for soft-tissue restoration.
• Detailed 12-month findings, quantitative analyses, and histology endpoints were held for scientific presentation, and for peer-reviewed publication.
• Conexeu noted that those preclinical volumes do not establish appropriate or safe dosing levels in humans.